ENO1 and pancreatic neoplasm: Approximately 64.7% of patients with pancreatic cancer with high ENO1 levels showed high-to-moderate differentiation, and 50% of patients with low ENO1 levels showed high-to-moderate differentiation (χ2 = 3.552, P = 0.042; Supplementary Table S1).